This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.
Rhythm Pharmaceuticals, Inc. (RYTM) Surges 42.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Biotech Stock Roundup: MRNA's Jab Update, ACER Down on Regulatory News & More
by Zacks Equity Research
Regulatory and other updates from Moderna (MRNA) and Acer (ACER) are a few key highlights from the biotech sector during the past week.
Rhythm Pharma (RYTM) Down on Mixed Imcivree Regulatory Updates
by Zacks Equity Research
The FDA approves label expansion of Rhythm Pharma's (RYTM) Imcivree to include Bardet-Biedl Syndrome patients. However, the FDA provides CRL for label expansion of the drug in Alstrom syndrome.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -7.14% and 38.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
by Zacks Equity Research
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Rhythm Pharmaceuticals (RYTM) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Rhythm (RYTM) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Rhythm Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rhythm Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Top Ranked Momentum Stocks to Buy for July 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 18th:
4 Best Performing Biotech Stocks of June: More Room to Run?
by Indrajit Bandyopadhyay
Biotech industry experiences a turnaround in June. Here are four stocks riding the rally.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
"Right To Try" Brings Good News for Biotech Sector: 5 Picks
by Gourav Kanti Bagchi
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
Will Rhythm Pharmaceuticals (RYTM) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Rhythm Pharmaceuticals, Inc. (RYTM)